leisure time -WSS

leisure time

author：fashion 2025-09-29 23:28:11 - browse：24

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Four alarming medical procedures we’re glad history forgot

WSS

Why health workers in Gaza are injured or die at high rates

FDA gives detailed accounting of AI

Impact of Dobbs ruling felt at reproductive medicine meeting

Overprescribed: High cost isn't America's only drug problem

Hospital price transparency does save money, advocate argues

Republican states more likely to report Covid vaccine side effects

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

In Memoriam: Notable people who died in 2023

Overprescribed: High cost isn't America's only drug problem

Apple is now the first public company to be valued at $3 trillion

NIH confirmation hearing shows politicization of research

Medical records are filled with copy

Covid silver lining: Unprecedented look at human immune system

Medical records are filled with copy

FDA gives detailed accounting of AI

Wildfire smoke exposes gaps in outdoor worker protections

Senate committee scrutinizes Medicare Advantage brokers

hotspot

Multiple sclerosis has subtypes with different best treatments: study

Harvard scientists, with Google, unveil the most detailed brain map ever

The EU Joint Clinical Assessment needs to live up to its promise

FDA struggles to regulate food additives, sometimes for decades

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Harvard scientists, with Google, unveil the most detailed brain map ever

leisure time

explore

hotspot

focus